In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Oncternal Therapeutics (ONCT – Research Report). The company’s shares closed yesterday at $0.31.
Selvaraju covers the Healthcare sector, focusing on stocks such as RAPT Therapeutics, MoonLake Immunotherapeutics, and Oncternal Therapeutics. According to TipRanks, Selvaraju has an average return of -14.3% and a 32.21% success rate on recommended stocks.
Currently, the analyst consensus on Oncternal Therapeutics is a Hold with an average price target of $1.30.
See today’s best-performing stocks on TipRanks >>
ONCT market cap is currently $17.97M and has a P/E ratio of -0.37.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ONCT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focus is on drug development on promising yet untapped biological pathways implicated in cancer progression. The company was founded in 1997 and is headquartered in San Diego, CA.
Read More on ONCT:
- Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference
- Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
- ONCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results
- Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors
